Now showing items 1-5 of 5
Cephalosporin-3’-diazeniumdiolate NO-donor prodrug PYRRO-C3D enhances azithromycin susceptibility of non-typeable Haemophilus influenzae biofilms
(American Society for Microbiology, 2016-12-05)
Objectives: PYRRO-C3D is a cephalosporin-3-diazeniumdiolate nitric oxide (NO)-donor prodrug designed to selectively deliver NO to bacterial infection sites. The objective of this study was to assess the activity of PYRRO-C3D ...
Low concentrations of nitric oxide modulate Streptococcus pneumoniae biofilm metabolism and antibiotic tolerance
(American Society for Microbiology, 2016-03-25)
Streptococcus pneumoniae is one of the key pathogens responsible for otitis media (OM), the most common infection in children and the largest cause of childhood antibiotic prescription. Novel therapeutic strategies that ...
Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis
Despite aggressive antibiotic therapy, bronchopulmonary colonization by Pseudomonas aeruginosa causes persistent morbidity and mortality in cystic fibrosis (CF). Chronic P. aeruginosa infection in the CF lung is associated ...
Cephalosporin-3’-diazeniumdiolate NO-donor prodrug PYRRO-C3D is active against Streptococcus pneumoniae biofilms despite the absence of -lactamases
Bacterial biofilms show high tolerance towards antibiotics and are a significant problem in clinical settings where they are a primary cause of chronic infections. Novel therapeutic strategies are needed to improve ...
Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa
(Oxford University Press, 2019-09-17)
Objectives: The cephalosporin nitric oxide (NO)-donor prodrug DEA-C3D (DiEthylAmin-Cephalosporin-3’- Diazeniumdiolate) has been showed to initiate the dispersal of biofilms formed by Pseudomonas aeruginosa laboratory strain ...